TSTrevor Shoemaker

Trevor Shoemaker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Trevor Shoemaker has a total of 253 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Investigation of Dinga Dinga: A Cluster of Bilateral Lower-Extremity Tremors—Bundibugyo District, Uganda, 2023–2024

    by Sophia Mulei, Daniel Orit, Mary J. Choi, Shannon Whitmer, Katrin S. Sadigh, Jimmy Baluku, Kami Smith, Alison Todres, Calvin R. Torach, Benigna Namara, et al.

    : In September 2023, a cluster of unexplained illness in women affecting their ability to stand/walk was reported at Bundibugyo Hospital, Uganda. Field investigations were conducted to verify reports, conduct active case finding, and identify potential causes using a hypothesis-generating questionnaire, a neurological examination tool, and a standardized laboratory panel. As of January 31, 2025, 136 patients were identified; all were female. Among 108 with age data, the median age was 18 years old, and all but one lived in Bundibugyo District. All reported bilateral lower-extremity tremors interfering with their ability to stand/walk that resolved when sitting or lying down. Of 75 women evaluated, 33 (44%) were acutely symptomatic at assessment. Tremors lasted between 4 days and 3 months. Of 90 women who provided symptom recurrence information, 20 (22%) reported recurrent episodes. No shared environmental exposures of concern were identified among 76 patients with data. Although limited female-specific exposures were noted, no known toxins were identified among patients. Blood specimens were submitted for laboratory testing, and 24 of 93 (26%) tested positive for Plasmodium . One of 34 (3%) tested positive for Shigella spp. Three of 87 (3%) were positive for Ekpoma virus 2 (EKV2), and 41 of 80 (51%) were anti-EKV2 IgG positive. Metagenomic sequencing confirmed two of the EKV2 cases and identified rickettsiae-specific reads in one individual. It is still unknown whether the cause is an infectious agent or an environmental toxin. This outbreak highlights the importance of strong field epidemiology and laboratory capacity in investigating emerging neurological syndromes.

  • Open Access

    Development and Qualification of a Nipah Virus Glycoprotein-Specific IgG ELISA for the Assessment of Human Antibody Responses

    by Mohammad Mamun Alam, Tahsin Tabassum Anonto, Sinthia Karim, Gathoni Kamuyu, Ali Azizi, Ayesha Siddika, Shadman Sakib Choudhury, Md Wasik Rahman, Anika Farzin, Dewan Imtiaz Rahman, et al.

    Background/Objectives: Nipah virus (NiV) is a highly pathogenic zoonotic virus with fatality rates exceeding 70% and causes recurring outbreaks in South and Southeast Asia. Reliable serological assays are critical for outbreak surveillance, diagnosis, and evaluation of vaccine-induced immune responses. This study aimed to develop and qualify an indirect enzyme-linked immunosorbent assay (ELISA) based on recombinant NiV glycoprotein G for the detection of virus-specific IgG antibodies in human serum. Methods: An indirect ELISA was developed and optimized for antigen concentration, blocking conditions, and serum dilution. The assay performance was evaluated using convalescent human sera from Bangladesh, along with the World Health Organization (WHO) International Standard for anti-Nipah virus antibodies, maintained and distributed by the National Institute for Biological Standards and Control (NIBSC). Analytical validation was conducted in accordance with ICH Q2 (R2) guidelines, including assessments of sensitivity, specificity, Precision, Linearity, and detection limits. Results: The assay demonstrated 100% sensitivity and specificity relative to reference sera. Intra-assay coefficients of variation ranged from 0.36% to 5.73%, and inter-assay variation was 4.16%, indicating high precision. The ELISA showed excellent Linearity (R2 > 0.995). The lower limit of detection was 0.51 IU/mL, and the lower limit of quantification was 0.98 IU/mL. Conclusions: The developed ELISA is a BSL-2-compatible, robust, and scalable platform suitable for serosurveillance and the assessment of vaccine-induced immunity in endemic regions. Calibration against an international standard supports its applicability for standardized antibody measurement. This assay provides a practical tool for NiV outbreak response and vaccine evaluation.


  • Open Access

    Social Media Promotion of Raw Date Palm Sap and Emerging Nipah Virus Transmission Risk in Bangladesh: Descriptive Analysis of Multisource Data

    by Kamal Ibne Amin Chowdhury, Faruq Abdulla, S M Zafor Shafique, Laila Afroza, Nisharggo Niloy, James Soren, Amlan Chakma, Md. Maniruzzaman Howlader, Md Taizul Islam, Muhammad Rashedul Alam, et al.

    Background: Nipah virus (NiV) infection is considered one of the deadliest infectious diseases, with a case fatality rate of approximately 71%. In Bangladesh, the primary risk factor for NiV infection is the consumption of raw date palm sap (DPS) contaminated with excreta from fruit bats (ie, members of the Pteropodidae family). Recently, the increasing use of social media among Bangladeshi youth has enabled business groups to widely advertise and sell raw DPS. This increased access, combined with young people perceiving consumption of raw DPS as an “adventurous event,” may facilitate an increase in incidences of NiV infection. Objective: We aimed to explore and document data from social media regarding raw DPS advertisements and consumption. Furthermore, we aimed to investigate the commercial distribution of raw DPS across the country. Methods: The data were accessed from common social media platforms used in Bangladesh, including Facebook and YouTube, between November 10, 2023, and January 31, 2024. We considered this period to capture public opinions, discussions, and reported incidents during the peak harvesting and consumption season of DPS. While DPS harvesting continues until March, early monitoring is essential for identifying the emerging concerns related to NiV transmission. Extracted variables were post dates and times, source locations, types of sources and posts, provider details (eg, sellers and gachis ), post descriptions, user reactions, views, comments, and shares. Particular emphasis was placed on identifying the districts of both DPS suppliers and recipients. We used R version 4.3.2 and Stata version 15 for analyzing statistical data and QGIS for geographic data. Results: Of 556 social media posts, 361 (64.9%) were advertisements promoting raw DPS. Few DPS-related posts were associated with raising awareness about DPS consumption and NiV infection. In total, 473,724 people interacted with the social media posts. The identification of supplier and recipient districts revealed 14 source districts of raw DPS. The majority of raw DPS were distributed from Rajshahi, Naogaon, Rajbari, and Faridpur, which are among the most NiV-prone districts. During the data collection period, we observed an average of 996 (SD 377) liters of raw DPS sold per day from multiple gachhis (sap collectors) and sellers (vendors) in Rajshahi. Conclusions: The marketing of raw DPS through digital media platforms has increased customer interest, as evidenced by the notably high level of public engagement observed on this topic within the Bangladeshi social media context. Distributing raw DPS using digital platforms is a marketing tool that significantly increases the availability of raw DPS to previously hard-to-reach markets and potentially increases individuals’ exposure to NiV infection. This study recommends a multidisciplinary approach, which incorporates context-specific public health investigations, policymaking, and digital media surveillance to address emerging public health concerns.


  • Open Access

    Factors Predicting the Outcome in Patients With Acute Encephalitis Syndrome: A Retrospective Analysis of Surveillance Data in Bangladesh

    by Dewan Imtiaz Rahman, Faruq Abdulla, Wasik Rahman Aquib, Md Mustafizur Rahman, Muhammad Rashedul Alam, Shadman Sakib Choudhury, Mohammad Rezaul Karim, Arifa Nazneen, Kamal Ibne Amin Chowdhury, Tonmoy Sarkar, et al.

    Introduction: Acute encephalitis syndrome (AES) is a severe inflammatory condition affecting the central nervous system, frequently leading to significant morbidity and mortality. Despite advancements in diagnostic techniques, the etiology of AES remains unidentified in a substantial number of cases, particularly in low‐ and middle‐income countries like Bangladesh. Understanding factors that predict outcomes in AES patients is crucial for improving management strategies and patient outcomes. Methods: We used data from the Nipah surveillance in Bangladesh, analyzing patients admitted with AES to 11 surveillance hospitals across diverse geographical regions in Bangladesh from January 2021 to December 2023. Trained surveillance team members screened patients and collected data through face‐to‐face interviews using a structured questionnaire, and surveillance physicians made decisions on enrollment as an AES case. Bivariate and multivariable logistic regression analyses were used to identify predictors of mortality. Results: A total of 12,603 AES patients were included, of whom 2,759 (22%) died. Mortality rates varied significantly across different administrative divisions, with the highest rates observed in the Rangpur division. Increased age, female sex, and delayed hospital admission were associated with higher odds of mortality. Patients from divisions like Rangpur and those aged 60 or over had notably higher odds of mortality, with adjusted odds ratios of 2.55 and 4.22, respectively. Clinical factors such as high pulse rate, ronchi, difficulty breathing, altered mental status, stiff neck, paralysis, and unconsciousness at admission were significantly associated with unfavorable outcomes. Discussion: The findings highlight significant geographical, demographic, and clinical predictors of mortality among AES patients in Bangladesh. Older age, delayed hospital admission, and certain reported clinical symptoms on admission increase the risk of death. The study underscores the importance of timely intervention and targeted management strategies, particularly in identified aforementioned high‐risk groups. Conclusion: Identifying predictors of adverse outcomes in AES patients can aid in developing early warning and triage systems, potentially enabling adequate resource allocation and the delivery of timely, personalized, and higher standard of care.

  • Open Access

    Rift Valley Fever Outbreak Investigation Associated with a Dairy Farm Abortion Storm, Mbarara District, Western Uganda, 2023

    by Luke Nyakarahuka, Shannon Whitmer, Sophia Mulei, Joanita Mutesi, Jimmy Baluku, Jackson Kyondo, Amy Whitesell, Carson Telford, Alex Tumusiime, Calvin Richie Torach, et al.

    In Africa, Rift Valley Fever poses a substantial risk to animal health, and human cases occur after contact with infected animals or their tissues. RVF has re-emerged in Uganda after nearly five decades, with multiple outbreaks recorded since 2016. We investigated a unique RVF outbreak associated with an animal abortion storm of 30 events and human cases on a dairy farm in Mbarara District, Western Uganda, in February 2023. Genomic analysis was performed, comparing animal and human RVF viruses (RVFV) circulating in the region. A cluster of thirteen human RVF cases and nine PCR-positive animals could directly be linked with the abortion storm. Overall, during the year 2023, we confirmed 61 human RVFV cases across Uganda, 88.5% of which were reported to have had direct contact with livestock, and a high case fatality rate of 31%. We recommend implementing extensive health education programs in affected communities and using sustainable mosquito control strategies to limit transmission in livestock, coupled with initiating animal vaccination trials in Uganda.

  • Severe Non–Donor-Derived Lymphocytic Choriomeningitis Virus Infection in 2 Solid Organ Transplant Recipients

    by Leanna E Sayyad, Kami L Smith, Katrin S Sadigh, Caitlin M Cossaboom, Mary J Choi, Shannon Whitmer, Debi Cannon, Inna Krapiunaya, Maria Morales-Betoulle, Pallavi Annambhotla, et al.

    Background: Lymphocytic choriomeningitis virus (LCMV) infection in immunocompromised hosts can result in disseminated disease, meningoencephalitis, and death. Published cases in transplant recipients have been traced to transmission from infected donors. We report 2 cases of serious, non–donor-derived LCMV infection in solid organ transplant recipients. Methods: Initial identification of LCMV infection was done by using metagenomic next-generation sequencing (mNGS). Subsequent evaluations and confirmatory testing involved molecular diagnostics, serology, and phylogenetic analysis. A detailed epidemiologic investigation was conducted. Results: LCMV was detected by mNGS in 2 solid organ transplant recipients from distinct donors. A heart transplant recipient (from donor 1) died of progressive, disseminated LCMV infection, while a kidney transplant recipient (from donor 2) with LCMV meningoencephalitis survived. A multistate laboratory and epidemiologic investigation of both donors and all their organ recipients was initiated. Postmortem samples were obtained from both donors, and pretransplant and/or posttransplant samples were obtained from 5 of the 6 organ recipients. mNGS, serologic, and real-time reverse-transcription polymerase chain reaction testing confirmed LCMV infection in both solid organ transplant recipients. Epidemiologic investigation revealed significant pretransplant rodent exposures for both LCMV-infected recipients. Laboratory studies for the other organ recipients from both donors were negative for LCMV infection. Conclusions: Our investigations suggest that LCMV infection in 2 solid organ transplant recipients originated from rodent exposure preceding transplantation and were not donor derived. Although uncommon, healthcare providers should be aware of LCMV-associated serious and life-threatening illness in immunocompromised hosts. Diagnostic modalities are limited to reference laboratories.


  • Open Access

    Utility of TaqMan Array Cards for detection of Acute febrile illness etiologies in patients suspected of Viral Hemorrhagic Fever Infections in Uganda

    by Gloria Grace Akurut, Luke Nyakarahuka, Shannon Whitmer, Dianah Namanya, K Kilama, Sophia Mulei, Jimmy Baluku, A Tumusime, Jackson Kyondo, Julius J Lutwama, et al.

    Introduction: Attributing a causative agent to acute febrile illnesses (AFI) remains a challenging diagnostic task for clinical and public health laboratories. The need for developing, validating and implementing a multi-pathogen diagnostic assay able to detect a wide range of AFI-associated pathogens should be prioritized in low-resource settings. The use of the previously developed Acute Febrile Illness TaqMan Array card (AFI-TAC), which detects 26 pathogens in less than 2 hours post-sample nucleic acid extraction, was selected for evaluation in Uganda. Methods: This was a cross-sectional retrospective study in which archived viral hemorrhagic fever (VHF)-negative blood and plasma samples were selected. Samples were previously tested and archived at the Uganda Virus Research Institute (UVRI)-Viral Hemorrhagic Fever (UVRI-VHF) Laboratory from August 2018 to March 2019 as part of the routine surveillance program. The VHF case definition included, temperature of ≥38.0 ºC, additionally with bleeding and any other febrile symptoms. Samples were then tested using an AFI-TAC for 35 potential pathogen targets. Selected positive samples were subsequently assessed using a second, pathogen-specific simplex PCR assay. Epidemiological data were linked to the laboratory findings to assess for risk factors for infection. Results: A total of 82 samples were selected for this study, of which 152 (83.52%) were from Uganda, 22 (12.09%) from the Democratic Republic of the Congo, 7 (3.85 %) from South Sudan, and 1 (0.55%) from Kenya. The median age of the patients was 27 years, with 145 (79.67%) samples from adults >18 years. Seven pathogens were detected with the most prevalent being Plasmodium spp. 26.92% (49/182) of which 69.4% (34/49) were Plasmodium falciparum, Yellow fever virus 2 (1.10 %), non-typhoidal Salmonella 3 (1.65%), Salmonella enterica serovar Typhi (1.10%), Leptospira spp. 1 (0.54%), Streptococcus pneumonia (0.55%), and Rickettsia spp. (0.55%). Epidemiological correlation revealed a significant relationship between case fatality (p=0.002) and disease while age, occupation, sex and disease were not significant. Cough was found to be the only clinical symptom associated with being infected with Plasmodium (p=0.016). Conclusion: The use of TAC is feasible, readily adoptable diagnostic assay for use in Uganda and will be useful when incorporated into the national testing algorithm for the differential diagnosis of AFI during an outbreak and surveillance.


  • Open Access

    A public, cross‐reactive glycoprotein epitope confounds Ebola virus serology

    by Markus H. Kainulainen, Jessica R. Harmon, Elif Karaaslan, Jackson Kyondo, Amy Whitesell, Sam Twongyeirwe, Jason H. Malenfant, Jimmy Baluku, Aaron Kofman, Éric Bergeron, et al.

    Ebola disease (EBOD) in humans is a severe disease caused by at least four related viruses in the genus Orthoebolavirus , most often by the eponymous Ebola virus. Due to human‐to‐human transmission and incomplete success in treating cases despite promising therapeutic development, EBOD is a high priority in public health research. Yet despite almost 50 years since EBOD was first described, the sources of these viruses remain undefined and much remains to be understood about the disease epidemiology and virus emergence and spread. One important approach to improve our understanding is detection of antibodies that can reveal past human infections. However, serosurveys routinely describe seroprevalences that imply infection rates much higher than those clinically observed. Proposed hypotheses to explain this difference include existence of common but less pathogenic strains or relatives of these viruses, misidentification of EBOD as something else, and a higher proportion of subclinical infections than currently appreciated. The work presented here maps B‐cell epitopes in the spike protein of Ebola virus and describes a single epitope that is cross‐reactive with an antigen seemingly unrelated to orthoebolaviruses. Antibodies against this epitope appear to explain most of the unexpected reactivity towards the spike, arguing against common but unidentified infections in the population. Importantly, antibodies of cross‐reactive donors from within and outside the known EBOD geographic range bound the same epitope. In light of this finding, it is plausible that epitope mapping enables broadly applicable specificity improvements in the field of serology.


  • Open Access

    Molecular characterization of the 2022 Sudan virus disease outbreak in Uganda

    by Stephen Balinandi, Shannon Whitmer, Sophia Mulei, Charity Nassuna, Godfrey Pimundu, Tonny Muyigi, Markus Kainulainen, Elizabeth Shedroff, Inna Krapiunaya, Florine Scholte, et al.

    Uganda experienced five Ebola disease outbreaks caused by Bundibugyo virus ( n = 1) and Sudan virus (SUDV) ( n = 4) from 2000 to 2021. On 20 September 2022, Uganda declared a fifth Sudan virus disease outbreak in the Mubende district, resulting in 142 confirmed and 22 probable cases by the end of the outbreak declaration on 11 January 2023. The earliest identified cases, through retrospective case investigations, had onset in early August 2022. From the 142 confirmed cases, we performed unbiased (Illumina) and SUDV-amplicon-specific (Minion) high-throughput sequencing to obtain 120 SUDV genome-and coding-complete sequences, representing 95.4% (104/109) of SVD-confirmed individuals within a sequence-able range (Ct ≤30) and 10 genome sequences outside of this range and 6 duplicate genome sequences. A comparison of the nucleotide genetic relatedness for the newly emerged Mubende variant indicated that it was most closely related to the Nakisamata SUDV sequence from 2011, represented a likely new zoonotic spillover event, and exhibited an inter- and intra-outbreak substitution rate consistent with previous outbreaks. The most recent common ancestor for the Mubende variant was estimated to have occurred in October and November 2021. The Mubende variant glycoprotein amino acid sequences exhibited 99.7% similarity altogether and a maximum of 96.1% glycoprotein similarity compared to historical SUDV strains from 1976. Integrating the genetic sequence and epidemiological data into the response activities generated a broad overview of the outbreak, allowing for quick fact-checking of epidemiological connections between the identified patients. IMPORTANCE: Ebola disease (EBOD) is a public health threat with a high case fatality rate. Most EBOD outbreaks have occurred in remote locations, but the 2013–2016 Western Africa outbreak demonstrated how devastating EBOD can be when it reaches an urban population. Here, the 2022 Sudan virus disease (SVD) outbreak in Mubende District, Uganda, is summarized, and the genetic relatedness of the new variant is evaluated. The Mubende variant exhibited 96% amino acid similarity with historic SUDV sequences from the 1970s and a high degree of conservation throughout the outbreak, which was important for ongoing diagnostics and highly promising for future therapy development. Genetic differences between viruses identified during the Mubende SVD outbreak were linked with epidemiological data to better interpret viral spread and contact tracing chains. This methodology should be used to better integrate discrete epidemiological and sequence data for future viral outbreaks.


  • Open Access

    A Countrywide Seroepidemiological Survey of Rift Valley Fever in Livestock, Uganda, 2017

    by Luke Nyakarahuka, Jackson Kyondo, Carson Telford, Amy Whitesell, Alex Tumusiime, Sophia Mulei, Jimmy Baluku, Caitlin M. Cossaboom, Deborah L. Cannon, Joel M. Montgomery, et al.

    : In 2016, an outbreak of Rift Valley fever was reported in the Kabale District in Uganda for the first time in 48 years. Three human cases were confirmed by polymerase chain reaction, and subsequent serological investigations revealed an overall IgG seropositivity of 13% in humans and 13% in animals. In response to this reemergence, we designed a countrywide survey to determine the seropositivity of anti-Rift Valley fever virus (RVFV) IgG antibodies in livestock. Samples were collected from 27 districts and tested for RVFV anti-IgG antibodies. A total of 3,181 livestock samples were tested, of which 54.4% were cattle (1,732 of 3,181), 34.3% were goats (1,091 of 3,181), and 11.3% were sheep (358 of 3,181). Overall RVFV seropositivity was 6.9% (221 of 3,181). Seroprevalence was greater in cattle (10.7%) compared with goats (2.6%) and sheep (2.0%), among females (7.5%) compared with males (5.2%), and among adults (7.6%) compared with juveniles (4.9%) and nurslings (6.4%). Exotic breeds and animals with a history of abortion or stillbirth also had greater odds of RVFV seropositivity. Animals grazed under tethering and paddocking had greater RVFV seropositivity compared with animals that grazed communally, and livestock in the western and eastern regions had the greatest seroprevalence. In a multivariate regression model, animal species (odds ratio [OR], 6.4; 95% CI, 3.5–11.4) and age (OR, 2.3; 95% CI, 1.4–3.6) were associated significantly with RVFV seropositivity. This study could be important in developing risk-based surveillance for early outbreak detection to limit the spread of RVFV in both human and animal populations.